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in some regions of
the United States.It is the goal of all practicing physicians to provide our patients with optimal medical and surgical
care for their condition. Part of providing this care is the ability to participate in clinical research.
While participating in research is fundamentally positive for the physician, the hospital, and the
patient, the requirements to successfully secure Medicare reimbursement for procedures used in
medical device trials under current regulations and processes has become exceedingly difﬁcult
in some regions of the United States.
As background, on September 8, 1995, the U.S. Food and Drug Administration (FDA) entered
into a memorandum of understanding with the administrator of the Medicare program, the
Health Care Finance Administration (HCFA) (now identiﬁed as the Centers for Medicare and
Medicaid Services [CMS]), to provide information about medical devices under an Investigational
Device Exemption (IDE) to aid in the agency’s reimbursement decisions regarding these new
technologies. Under this agreement, certain devices could be viewed as “reasonable and necessary”
by Medicare, and treatments could be covered by Medicare if all other applicable coverage
requirements are met. The intent of this memorandum of understanding was to provide Medicare
beneﬁciaries access to novel or next-generation medical devices, depending on the FDA classiﬁ-
cation provided to HCFA (CMS). Under federal regulation, Medicare is required to cover the use
of devices that are “reasonable and necessary for the diagnosis and treatment of an injury or illness
or to improve the functioning of a malformed body member.” To assist CMS with the deter-
mination of “reasonable and necessary,” the FDA created categories of devices depending on their
novelty or similarity to existing technologies. The idea was that devices similar to existing devices
or procedures should be covered while the product was still under investigation in an FDA-
approved IDE study. The regulations also allow CMS to delegate responsibility for determining
what is or is not “reasonable and necessary” to its regional Medicare Administrative Contractors
(MACs) for individual trial coverage. Herein lays the opportunity for variable interpretation of
the “reasonable and necessary” threshold for CMS coverage and in many instances, inability for
Medicare beneﬁciaries to have access to new therapies that are available only through participation
in clinical research studies.
The inconsistency with which the different MAC medical directors review and approve (or do
not approve) coverage has caused widespread dissatisfaction among clinical trial sponsors, inves-
tigators, and clinical sites. The MAC medical directors make decisions independently and have no
centralized reporting structure that ensures uniform policy making. The frequency in MAC
changes across the regions, MAC stafﬁng turnover (both medical directors and IDE coordinators),
and the variable depth and quality of clinical protocol reviews has greatly hindered efﬁcient and
timely patient enrollment. There are numerous examples that have hindered conduct and access to
clinical research. In one instance, a MAC (medical director and team) reviewed and approved a
clinical site within 3 days while other sites in another MAC region waited more than 30 days for
the same study to be reviewed and approved. Another medical director decided to approve only
10% of a site’s potential population, considerably limiting enrollment. Still other regional medical
directors have refused approval unless speciﬁc revisions were made to an already FDA-approved
protocoldan impractical demand that is disruptive to the scientiﬁc validity of a study by imposing
an inconsistent protocol implemented across trial sites. Finally, a medical director may refuse to
review studies to which the FDA has granted approval “with conditions,” even when the FDA has
agreed that there are no safety issues, instead insisting on “approval without conditions” from the
FDA. Such approval may not be received until clinical studies are already underway or are
completed. Despite earlier conditional approval, for example, ﬁnal FDA approval of the ﬁrst
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641transcatheter aortic valve application occurred just
5 months prior to completion of patient enrollment.
Among centers whose Medicare reimbursement was
delayed, many otherwise eligible patients could not be
enrolled in the study and thus could not receive
treatment. Furthermore, the FDA itself has stated that
approval “with conditions” is often sufﬁcient to initiate
trials, because outstanding issues do not pose safety
concerns to patients that would preclude enrollment.
These types of inconsistencies have created an
atmosphere of uncertainty among many physician
investigators, hospital research programs, and medical
device manufacturers that have adverse consequences
on clinical research in the United States. To compli-
cate matters further, many hospitals now refuse to
issue an institutional review board (ethics review)
approval until Medicare approval is granted. Likewise,
some hospitals even refuse to screen or enroll
commercially insured patients until Medicare approves
the study, a decision predicated on concern regarding
accusations of discrimination against Medicare
patients. Based on these obstacles, one can see that the
entire clinical trial process in the United States could
grind to a halt, thwarting the development and
evaluation of new potentially beneﬁcial or life-saving
medical device innovations, therefore driving these
activities out of the United States. Attention is being
focused on the longer time required to bring new
medical device technology to patients in the United
States compared with those in other parts of the
world. Although much of the concern has been
directed toward FDA review and approval, an under-
appreciated obstacle is that even after the FDA has
deemed that a clinical study of an investigationaldevice can commence, this Medicare reimbursement
process can delay or disrupt clinical research.
At present, no formal solution has been proposed to
develop a more efﬁcient and predictable process. One
possibility would be designation of a central MAC to
approve or deny coverage for all Medicare beneﬁciaries
for all MACs. Enhanced communication with the
FDA prior to the agency’s approval of a protocol may
also preempt misunderstandings related to protocol
interpretation among MACs. Given that there is no
formal method of determining variability and time
delays in approval across MACs, such a policy would
establish a record of accountability. Such measures
would advance the consistency and reliability within
the MAC review process. Participation in clinical
research is a privilege for investigators, practitioners,
and patients. A fundamental tenet of research should
be equal and have timely access to such opportunities.
While there is no single, rate-limiting step that delays
the evaluation and availability of innovative medical
treatments to patients in the United States, addressing
the inconsistent Medicare reimbursement process will
be an important step forward.Acknowledgments
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